It seems very promising to find out more about the physiological role of KLK10. Consequently, it might be possible to use inhibitors of kallikreins to disrupt interactions between the tumour and its environment and thereby reduce disease progression in patients with pancreatic cancer. The gene discussed is KLK4; the disease is familial pancreatic carcinoma.